Indegene valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024
Price multiples — at each FY-end close
35.04×———
4.29×———
3.49×———
23.75×———
Enterprise multiples
3.21×———
19.39×———
25.91×———
Yield
2.9%———
4.2%———
Reference — adjusted share basis
₹598.95———
₹17.09₹16.68₹16.91₹14.33
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDGN₹598.95

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹14,405 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E———35.04
P/B———4.29
P/Sales———3.49
Price to Free Cash Flow———23.75
Enterprise Multiples
EV/Sales———3.21
EV/EBITDA———19.39
EV/EBIT———25.91
Yield
Earnings Yield %———2.85
FCF Yield %———4.21
Reference — adjusted share basis
Price (FY-end close, adj.)———598.95
EPS (adj.)14.3316.9116.6817.09
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.